Literature DB >> 18491042

Mice deficient in both pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide survive, but display growth retardation and sex-dependent early death.

Pawel Niewiadomski1, Anne-Claire Coûté-Monvoisin, Catalina Abad, Danny Ngo, Adrian Menezes, James A Waschek.   

Abstract

Pituitary adenylyl cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are two closely related neuropeptides exhibiting overlapping activities which have actions on almost every organ system of the body. To determine if these peptides exert essential but redundant functions, we interbred VIP- and PACAP-deficient mice to obtain VIP/PACAP double knockout (DKO) mice. DKO mice had normal birth weights and survived to weaning, but exhibited a dramatic postnatal growth rate reduction. Analyses at postnatal day 16 indicated that all organs examined except the brain were reduced in mass by 40-70% compared to mixed background controls, with the thymus and spleen most profoundly affected. Brain size was also significantly reduced, but by only 10%. The reduced growth rate of DKO mice was associated with reduced serum concentrations of insulin-like growth hormone-1 (IGF-1), but unchanged levels of growth hormone. Despite the normal survival of DKO mice up to the weaning stage, many subsequently experienced early sudden death, with only 48% of females and 82% of males surviving past 6 months. The results indicate that a significant percentage of mice deficient in both VIP and PACAP survive to adulthood, but their growth rate is profoundly affected, and that females in particular exhibit high rate of mortality after about 3 months of age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491042     DOI: 10.1007/s12031-008-9085-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

Review 1.  The significance of vasoactive intestinal peptide in immunomodulation.

Authors:  Mario Delgado; David Pozo; Doina Ganea
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

Review 2.  Hormonal and nutritional regulation of IGF-I and its binding proteins.

Authors:  L E Underwood; J P Thissen; S Lemozy; J M Ketelslegers; D R Clemmons
Journal:  Horm Res       Date:  1994

3.  Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period.

Authors:  J Y Wu; K A Henins; P Gressens; I Gozes; M Fridkin; D E Brenneman; J M Hill
Journal:  Peptides       Date:  1997       Impact factor: 3.750

4.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice.

Authors:  Beatrice A Girard; Vincent Lelievre; Karen M Braas; Tannaz Razinia; Margaret A Vizzard; Yevgeniya Ioffe; Rajaa El Meskini; Gabriele V Ronnett; James A Waschek; Victor May
Journal:  J Neurochem       Date:  2006-10       Impact factor: 5.372

6.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

Authors:  F Jamen; K Persson; G Bertrand; N Rodriguez-Henche; R Puech; J Bockaert; B Ahrén; P Brabet
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice.

Authors:  Christiane Otto; Lutz Hein; Marc Brede; Roland Jahns; Stefan Engelhardt; Hermann-Josef Gröne; Günther Schütz
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

8.  Organ-selective growth in the offspring of protein-restricted mothers.

Authors:  M Desai; N J Crowther; A Lucas; C N Hales
Journal:  Br J Nutr       Date:  1996-10       Impact factor: 3.718

9.  Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate.

Authors:  Mark A Asnicar; Anja Köster; Mark L Heiman; Frank Tinsley; Dennis P Smith; Elizabeth Galbreath; Niles Fox; Yanfei Linda Ma; Werner F Blum; Hansen M Hsiung
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

10.  Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior.

Authors:  Maria A Lim; Conor M Stack; Katrina Cuasay; Madeleine M Stone; Hewlet G McFarlane; James A Waschek; Joanna M Hill
Journal:  Int J Dev Neurosci       Date:  2008-03-14       Impact factor: 2.457

View more
  1 in total

1.  Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazolone-induced allergic contact dermatitis in mice.

Authors:  Agnes Kemény; Dóra Reglodi; Renáta Cseharovszky; Hitoshi Hashimoto; Akemichi Baba; János Szolcsányi; Erika Pintér; Zsuzsanna Helyes
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.